跳到正文
WHO 药品预认证与检查动态·· 12 天前AI 评分49

Viyash Scientific Limited 生产的原料药通过 WHO 预认证

Active Pharmaceutical Ingredient (API) Prequalified

AI 导读

Viyash Scientific Limited 生产的原料药已通过 WHO 药品预认证团队的原料药预认证程序。该原料药用于含富马酸替诺福韦二吡呋酯的制剂,适应症为 HIV/AIDS。WHO 原料药预认证包括原料药主文件(APIMF)评估与原料药生产场地 GMP 符合性评估两部分。

正文 · 原文

News

11 November, 2026 - 00:12 (CET)

Announcement

<Tenofovir disoproxil fumarate> manufactured by Viyash Scientific Limited has been prequalified by the WHO Prequalification Team medicines under its API prequalification procedure.

Good-quality APIs are vital to the production of good-quality medicines.  WHO prequalification of APIs facilitates production of quality medicines by identifying such APIs for use by manufacturers of finished pharmaceutical products (FPPs). FPPs containing tenofovir disoproxil fumarate are used in the therapeutic area of HIV/AIDS.

API prequalification consists of a comprehensive evaluation procedure that has two components: assessment of the API master file (APIMF) to verify compliance with WHO norms and standards, and evaluation of the sites of API manufacture to verify compliance with WHO Good Manufacturing Practice requirements.

Links

来源:WHO 药品预认证与检查动态 · extranet.who.int